Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jul 27, 2026
Why Is Acadia Healthcare Company (ACHC) Stock Up +1.47% Today?

Why Is Acadia Healthcare Company (ACHC) Stock Up +1.47% Today?

Key Takeaways

  • Acadia Healthcare shares gained 1.47% on Friday, closing at $34.51, up $0.50 from the prior session's close of $34.01, extending a remarkable multi-week rally.
  • A wave of analyst price-target increases — including bullish revisions from Guggenheim, KeyBanc, TD Cowen, and UBS — has fueled sustained buying momentum throughout July.
  • Anticipation ahead of Q2 2026 earnings, scheduled for release on Tuesday, July 28, has kept the stock in focus as traders position for the company's next results.
  • The stock is up approximately 143% year-to-date, reflecting a powerful turnaround narrative under returning leadership and improving operational metrics.
  • Elevated short interest — roughly 36.6% of the float — has amplified upward moves as bearish bets face pressure during the rally.
  • Investors now turn their attention to Tuesday's earnings release, where revenue, EPS, and forward guidance will determine whether the rally holds or reverses.

Opening Summary

ACHC — Acadia Healthcare Company, Inc., the largest stand-alone behavioral healthcare provider in the United States — saw its stock rise 1.47% in Friday's trading session. Shares closed at $34.51, adding $0.50 from Thursday's closing price of $34.01. The move marked the latest leg in a sustained rally that has propelled the behavioral health operator's market capitalization to roughly $3.17 billion. Headquartered in Franklin, Tennessee, Acadia operates a network of approximately 275 facilities with roughly 12,400 beds across 40 states and Puerto Rico, providing inpatient psychiatric, substance abuse treatment, and outpatient behavioral health services.

Analyst Upgrades and Price-Target Increases Drive Momentum

A cluster of bullish analyst actions in July has been the primary catalyst behind ACHC's extraordinary run. On July 14, KeyBanc raised its price target to $40 from $30, maintaining an Overweight rating, while TD Cowen lifted its target to $36 from $30 with a Buy rating. Earlier in the month, UBS boosted its target to $39 from $31, and Guggenheim raised its target to $38 from $31. These revisions collectively signal Wall Street's growing conviction that Acadia's turnaround — anchored by returning CEO leadership, bed-capacity expansion, and improved earnings visibility — is gaining real traction. The stock has now blown past the average analyst price target of approximately $32, suggesting the market is pricing in further operational improvements ahead of the company's Q2 report.

Earnings Anticipation Adds Fuel

Acadia Healthcare is scheduled to release its second-quarter 2026 results after the market closes on Tuesday, July 28, with a conference call set for Wednesday, July 29. Analysts are looking for earnings of approximately $0.33 per share on revenue near $848 million, while the company's own guidance calls for EPS in the $0.30–$0.40 range. The company beat expectations handily in Q1, delivering $0.37 per share versus the $0.28 consensus on revenue of $828.8 million — a 7.6% year-over-year increase. That beat, combined with raised full-year guidance for adjusted EBITDA and EPS, set the stage for the current rally. With the earnings event now just one trading day away, positioning flows and anticipation of another potential beat have contributed to Friday's gains.

Turnaround Narrative and Institutional Accumulation

Since the start of 2026, ACHC has undergone a dramatic transformation. The stock entered the year at $14.19 and has surged roughly 143% year-to-date, driven by a combination of new management, cost discipline, and improving facility-level performance. The return of former CEO leadership, the appointment of David Duckworth as Interim CFO, and a strategic focus on boosting underperforming assets have restored investor confidence. Institutional investors have taken note: Principal Financial Group increased its stake by 27.4% in the first quarter, while other large holders — including Wellington Management, Goldman Sachs, and Jefferies Financial Group — have materially expanded their positions. The stock's addition to the Russell 2000 Index after being dropped from the Russell 1000 has also broadened its institutional ownership base.

Market Context and Trading Activity

Friday's session saw roughly 2.3 million shares change hands, modestly below the three-month average volume of approximately 3.1 million. The stock traded in a range of $34.30 to $35.29, briefly testing but not surpassing the 52-week high of $35.83 set earlier in the week. The broader healthcare provider sector has been relatively steady, with peers such as THC and HCA posting solid Q2 results that buoyed sentiment across the group. Acadia's rally has far outpaced both the healthcare sector and the broader S&P 500, reflecting company-specific catalysts rather than a simple sector tailwind. Notably, short interest remains exceptionally elevated at roughly 36.6% of the float — approximately 21.8 million shares — which has amplified upside moves as short sellers face mounting pressure during the stock's relentless ascent.

What Comes Next for ACHC

The immediate focus for ACHC is Tuesday's Q2 earnings release. Beyond the headline numbers, investors will scrutinize same-facility volume trends, bed-ramp progress at newer facilities, margin trajectories, and updated full-year guidance. Key risks include the company's elevated debt load of roughly $2.69 billion, lingering legal overhangs including a $105 million jury verdict against a subsidiary, and the possibility that the rapid share-price appreciation has already priced in optimistic assumptions about the turnaround. On the bullish side, sustained demand for behavioral health services, expanding insurance coverage, and operational improvements under new leadership could extend the rally further. With the stock having more than tripled from its January lows, the Q2 report represents a critical test of whether the fundamentals can justify the extraordinary re-rating.

Trending AI Robots

For traders seeking data-driven strategies in volatile markets like the one ACHC is navigating, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest real-time performance under current market dynamics are featured in this actively maintained section. Bots span a range of strategies, timeframes, and traded symbols, allowing users to identify approaches aligned with their own risk tolerance and market outlook. Explore the Trending AI Robots page to discover which automated strategies are currently outperforming.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ACHC

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


ACHC in downward trend: price expected to drop as it breaks its higher Bollinger Band on September 22, 2026

ACHC broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 30 of the 39 cases the stock fell afterwards. This puts the odds of success at 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

The Aroon Indicator for ACHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 62 cases where ACHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ACHC as a result. In 66 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for ACHC just turned positive on October 05, 2026. Looking at past instances where ACHC's MACD turned positive, the stock continued to rise in 30 of 48 cases over the following month. The odds of a continued upward trend are 62%.

Following a +7.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHC advanced for three days, in 193 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ACHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.313) is normal, around the industry mean (208.195). P/E Ratio (20.207) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.758) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.84B. The market cap for tickers in the group ranges from 20.9K to 93.66B. HCA holds the highest valuation in this group at 93.66B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 24%. AMN experienced the highest price growth at 8%, while NIVF experienced the biggest fall at -68%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 32%. For the same stocks of the Industry, the average monthly volume growth was 67% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 45
Price Growth Rating: 55
SMR Rating: 66
Profit Risk Rating: 88
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
ACHC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of a network of behavioral health centers

Industry HospitalNursingManagement

Industry
Medical Or Nursing Services
Address
4020 Aspen Grove Drive
Phone
+1 615 861-6000
Employees
25000
Web
https://www.acadiahealthcare.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks
Shares of Robinhood Markets are down approximately 6.15% in Thursday's intraday session, trading around $65.80 after closing at $70.11 on April 1, 2026. Wolfe Research delivered a sharp blow by cutting its price target on HOOD by 30%, citing persistent weakness in crypto trading volumes as a core drag on revenue.
Shares of Iridium Communications (IRDM) surged approximately +11.00% in Thursday's session, rising from a prior close of $28.52 to an intraday high near $31.76. A broad-based equity market rally drove significant gains across communication and satellite sector stocks, as investor sentiment sharply reversed after days of macro-driven selling pressure tied to tariff fears.
AirSculpt Technologies, Inc. (AIRS) stands out as a leading provider of minimally invasive body contouring procedures through its Elite Body Sculpture brand. The company specializes in proprietary AirSculpt treatments that remove fat and tighten skin without general anesthesia. These include options like AirSculpt+, AirSculpt Smooth for cellulite reduction, and specialized fat transfer procedures such as Power BBL for Brazilian butt lifts, Up a Cup for breast enhancement, and Hip Flip for hourglass contouring. Based in Miami Beach, Florida, and founded in 2012, AIRS operates centers across the United States, Canada, and the United Kingdom.
ASRT stock surged +66% over the past 30 days, driven by strong Q4 2025 earnings beat and optimistic 2026 guidance highlighting Rolvedon growth. Over the past quarter, the stock rose +117%, fueled by improving gross margins, stable product demand, and analyst price target increases.